YD Bio Limited (YDES)

YD Bio Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Revenue	0.51	0.35	0.36
Revenue Growth (YoY)	45.76%	-3.84%	-
Cost of Revenue	0.36	0.2	0.23
Gross Profit	0.16	0.15	0.13
Selling, General & Admin	1.13	0.16	0.18
Research & Development	0.49	-	-
Operating Expenses	1.62	0.16	0.18
Operating Income	-1.46	-0.01	-0.04
Interest Expense	-0	-0	-0
Interest & Investment Income	0.01	0	0
Other Non Operating Income (Expenses)	0.06	0.03	0.06
EBT Excluding Unusual Items	-1.39	0.02	0.01
Gain (Loss) on Sale of Investments	-	-	-0.06
Pretax Income	-1.39	0.02	-0.05
Income Tax Expense	0.03	0	0
Net Income	-1.41	0.01	-0.05
Net Income to Common	-1.41	0.01	-0.05
Shares Outstanding (Basic)	1	1	-
Shares Outstanding (Diluted)	1	1	-
Shares Change (YoY)	4.01%	-	-
EPS (Basic)	-1.29	0.01	-
EPS (Diluted)	-1.29	0.01	-
Free Cash Flow	-1.91	-0.06	0.07
Free Cash Flow Per Share	-1.75	-0.05	-
Gross Margin	30.44%	43.82%	36.58%
Operating Margin	-286.45%	-2.81%	-12.33%
Profit Margin	-276.58%	3.87%	-13.95%
Free Cash Flow Margin	-374.58%	-15.98%	19.21%
EBITDA	-1.36	-0.01	-0.04
EBITDA Margin	-265.93%	-2.11%	-11.34%
D&A For EBITDA	0.1	0	0
EBIT	-1.46	-0.01	-0.04
EBIT Margin	-286.45%	-2.81%	-12.33%
Effective Tax Rate	-	23.17%	-

Updated Apr 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q